This is the final submission of the collaborative R01 MH094421 Psychiatric GWAS Consortium: Genomic Follow-Up Next-Gen Sequencing &Genotyping. The overall goal of this application is ambitious:
we aim to generate a trustworthy, high-confidence """"""""maps"""""""" of the genetic architecture of centrally important psychiatric diseases. Such maps consist of systematic and comprehensive evaluation of the allelic spectrum for these disorders including rare exonic, common SNP, and copy number variation. The feasibility of our aims is supported by the track record of the first iteration of the Psychiatric GWAS Consortium (""""""""PGC1"""""""") where we united nearly all major groups in the field into a harmonious and functional entity and completed our initial aims to a high scientific standard. Psychiatric diseases are compelling targets for intensive research: they are mostly idiopathic, first-rank public health problems, and cause enormous morbidity, mortality, and personal/societal cost. Consistent with the NIH mission, our goal is to elucidate fundamental knowledge of these diseases. In this """"""""PGC2"""""""" application, we propose to capitalize on prior NIH investments and on the success of PGC1 for the next logical set of aims. The PGC2 aims are """"""""large-scale"""""""" (largest sample sizes ever in the field) and """"""""comprehensive"""""""" (via the careful application of multiple genomic-scale technologies). Our focus is comprehensive in other senses - the PGC encompasses nearly the entire field, and we aim to elucidate the allelic spectrum of these disorders by integrating empirical data for all readily measurable types of genetic variation of etiological relevance (common SNP, rare exonic, and rare and common copy number variation - what we term the """"""""map""""""""). There are three analytic aims - systematically to assess copy number variation, to create a pipeline for the analysis of exome data (and eventually whole-genome data), and to investigate genetic associations that span traditional disease boundaries. Finally, we propose to develop the """"""""PsychChip"""""""" a custom 20,000 probe array targeting common SNP, exonic, and CNVs that would then be used to genotype 115,082 subjects. The PGC2 impact is potentially very large - a fundamental understanding of the genetics of these diseases would be a major milestone in psychiatry and in biomedicine.

Public Health Relevance

Psychiatric disorders cause enormous human suffering and cost to society. Our goal is rapidly to learn more about the genetics of some of these disorders. We propose to do this via the largest consortium ever constructed in the field, and by the use of several genetic technologies.

Agency
National Institute of Health (NIH)
Institute
National Institute of Mental Health (NIMH)
Type
Research Project--Cooperative Agreements (U01)
Project #
5U01MH094411-02
Application #
8468748
Study Section
Special Emphasis Panel (ZRG1-PSE-M (03))
Program Officer
Addington, Anjene M
Project Start
2012-05-10
Project End
2016-03-31
Budget Start
2013-04-01
Budget End
2014-03-31
Support Year
2
Fiscal Year
2013
Total Cost
$587,639
Indirect Cost
$152,847
Name
University of California San Diego
Department
Psychiatry
Type
Schools of Medicine
DUNS #
804355790
City
La Jolla
State
CA
Country
United States
Zip Code
92093
Marshall, Christian R (see original citation for additional authors) (2017) Contribution of copy number variants to schizophrenia from a genome-wide study of 41,321 subjects. Nat Genet 49:27-35
Lee, Inkyu S; Carvalho, Claudia M B; Douvaras, Panagiotis et al. (2015) Characterization of molecular and cellular phenotypes associated with a heterozygous CNTNAP2 deletion using patient-derived hiPSC neural cells. NPJ Schizophr 1:
Kusenda, Mary; Vacic, Vladimir; Malhotra, Dheeraj et al. (2015) The Influence of Microdeletions and Microduplications of 16p11.2 on Global Transcription Profiles. J Child Neurol 30:1947-53
Lin, Guan Ning; Corominas, Roser; Lemmens, Irma et al. (2015) Spatiotemporal 16p11.2 protein network implicates cortical late mid-fetal brain development and KCTD13-Cul3-RhoA pathway in psychiatric diseases. Neuron 85:742-54
Levinson, Douglas F; Mostafavi, Sara; Milaneschi, Yuri et al. (2014) Genetic studies of major depressive disorder: why are there no genome-wide association study findings and what can we do about it? Biol Psychiatry 76:510-2
Mulle, Jennifer Gladys; Pulver, Ann E; McGrath, John A et al. (2014) Reciprocal duplication of the Williams-Beuren syndrome deletion on chromosome 7q11.23 is associated with schizophrenia. Biol Psychiatry 75:371-7
Rippey, Caitlin; Walsh, Tom; Gulsuner, Suleyman et al. (2013) Formation of chimeric genes by copy-number variation as a mutational mechanism in schizophrenia. Am J Hum Genet 93:697-710
Guha, Saurav; Rees, Elliott; Darvasi, Ariel et al. (2013) Implication of a rare deletion at distal 16p11.2 in schizophrenia. JAMA Psychiatry 70:253-60
Malhotra, Dheeraj; Sebat, Jonathan (2012) CNVs: harbingers of a rare variant revolution in psychiatric genetics. Cell 148:1223-41
Psychiatric GWAS Consortium Coordinating Committee; Cichon, Sven; Craddock, Nick et al. (2009) Genomewide association studies: history, rationale, and prospects for psychiatric disorders. Am J Psychiatry 166:540-56